Dialysis anticoagulants are mainly categorized into low molecular heparin, sodium citrate, argatroban, etc. There is no such thing as which one is better, and the choice is mainly based on the patient’s own situation. Low molecular heparin is a widely used anticoagulant, with the advantages of good injection absorption, long half-life, high bioavailability, and no need for monitoring, etc., and its application in the clinic is expanding. Sodium citrate can promote the formation of thrombomodulin, thrombin and fibrin, and the coagulation process is inhibited, thus preventing blood coagulation, which is mostly used in patients with bleeding from other parts of the body, such as gastrointestinal bleeding. Argatroban is a thrombin inhibitor that inhibits the binding of blood clots and dissolves thrombin. For general dialysis patients, low molecular heparin anticoagulation is usually used if there is no contraindication. For patients with bleeding conditions, sodium citrate and argatroban anticoagulation are recommended, and argatroban anticoagulation is preferred in patients with heparin-induced thrombocytopenia if present. All of the above drugs should be used in accordance with medical advice. If an adverse reaction occurs after the injection, the doctor should be informed promptly to identify the cause of the disease, and treatment should be carried out under the guidance of the doctor.